The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy

Natalizumab is a monoclonal antibody against α4-integrin approved for the treatment of multiple sclerosis (MS) due to a positive effect on clinical and magnetic resonance imaging (MRI) outcome measures. However, one relatively rare but serious side effect of this drug is a higher risk of developing...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Multiple sclerosis Ročník 19; číslo 14; s. 1826 - 1840
Hlavní autoři: Wattjes, Mike P, Richert, Nancy D, Killestein, Joep, de Vos, Marlieke, Sanchez, Esther, Snaebjornsson, Petur, Cadavid, Diego, Barkhof, Frederik
Médium: Journal Article
Jazyk:angličtina
Vydáno: London, England SAGE Publications 01.12.2013
Sage Publications
Sage Publications Ltd
Témata:
ISSN:1352-4585, 1477-0970, 1477-0970
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Natalizumab is a monoclonal antibody against α4-integrin approved for the treatment of multiple sclerosis (MS) due to a positive effect on clinical and magnetic resonance imaging (MRI) outcome measures. However, one relatively rare but serious side effect of this drug is a higher risk of developing progressive multifocal leukoencephalopathy (PML). Since the FDA approval, more than 300 natalizumab-associated PML cases have been documented among more than 100,000 treated MS patients. MRI is a crucial tool in the surveillance of patients treated with natalizumab in order to detect possible signs of PML in the asymptomatic stage. Although classical imaging characteristics of PML are well established, MRI findings in natalizumab-associated PML, particularly in early disease stages, show rather new and heterogeneous imaging findings including different patterns of inflammation with contrast enhancement. This review provides a comprehensive overview of the heterogeneous imaging findings in natalizumab-associated PML in the context of the underlying pathophysiology, histopathology, and the diagnostic procedure. We describe the MRI patterns of PML lesion evolution and complications including immune reconstitution inflammatory syndrome (IRIS). Finally, we present guidelines to differentiate MRI findings in PML from inflammatory demyelinating lesions, to facilitate the early diagnosis of PML in patients treated with natalizumab.
AbstractList Natalizumab is a monoclonal antibody against α4-integrin approved for the treatment of multiple sclerosis (MS) due to a positive effect on clinical and magnetic resonance imaging (MRI) outcome measures. However, one relatively rare but serious side effect of this drug is a higher risk of developing progressive multifocal leukoencephalopathy (PML). Since the FDA approval, more than 300 natalizumab-associated PML cases have been documented among more than 100,000 treated MS patients. MRI is a crucial tool in the surveillance of patients treated with natalizumab in order to detect possible signs of PML in the asymptomatic stage. Although classical imaging characteristics of PML are well established, MRI findings in natalizumab-associated PML, particularly in early disease stages, show rather new and heterogeneous imaging findings including different patterns of inflammation with contrast enhancement. This review provides a comprehensive overview of the heterogeneous imaging findings in natalizumab-associated PML in the context of the underlying pathophysiology, histopathology, and the diagnostic procedure. We describe the MRI patterns of PML lesion evolution and complications including immune reconstitution inflammatory syndrome (IRIS). Finally, we present guidelines to differentiate MRI findings in PML from inflammatory demyelinating lesions, to facilitate the early diagnosis of PML in patients treated with natalizumab.Natalizumab is a monoclonal antibody against α4-integrin approved for the treatment of multiple sclerosis (MS) due to a positive effect on clinical and magnetic resonance imaging (MRI) outcome measures. However, one relatively rare but serious side effect of this drug is a higher risk of developing progressive multifocal leukoencephalopathy (PML). Since the FDA approval, more than 300 natalizumab-associated PML cases have been documented among more than 100,000 treated MS patients. MRI is a crucial tool in the surveillance of patients treated with natalizumab in order to detect possible signs of PML in the asymptomatic stage. Although classical imaging characteristics of PML are well established, MRI findings in natalizumab-associated PML, particularly in early disease stages, show rather new and heterogeneous imaging findings including different patterns of inflammation with contrast enhancement. This review provides a comprehensive overview of the heterogeneous imaging findings in natalizumab-associated PML in the context of the underlying pathophysiology, histopathology, and the diagnostic procedure. We describe the MRI patterns of PML lesion evolution and complications including immune reconstitution inflammatory syndrome (IRIS). Finally, we present guidelines to differentiate MRI findings in PML from inflammatory demyelinating lesions, to facilitate the early diagnosis of PML in patients treated with natalizumab.
Natalizumab is a monoclonal antibody against α4-integrin approved for the treatment of multiple sclerosis (MS) due to a positive effect on clinical and magnetic resonance imaging (MRI) outcome measures. However, one relatively rare but serious side effect of this drug is a higher risk of developing progressive multifocal leukoencephalopathy (PML). Since the FDA approval, more than 300 natalizumab-associated PML cases have been documented among more than 100,000 treated MS patients. MRI is a crucial tool in the surveillance of patients treated with natalizumab in order to detect possible signs of PML in the asymptomatic stage. Although classical imaging characteristics of PML are well established, MRI findings in natalizumab-associated PML, particularly in early disease stages, show rather new and heterogeneous imaging findings including different patterns of inflammation with contrast enhancement. This review provides a comprehensive overview of the heterogeneous imaging findings in natalizumab-associated PML in the context of the underlying pathophysiology, histopathology, and the diagnostic procedure. We describe the MRI patterns of PML lesion evolution and complications including immune reconstitution inflammatory syndrome (IRIS). Finally, we present guidelines to differentiate MRI findings in PML from inflammatory demyelinating lesions, to facilitate the early diagnosis of PML in patients treated with natalizumab.
Natalizumab is a monoclonal antibody against α4-integrin approved for the treatment of multiple sclerosis (MS) due to a positive effect on clinical and magnetic resonance imaging (MRI) outcome measures. However, one relatively rare but serious side effect of this drug is a higher risk of developing progressive multifocal leukoencephalopathy (PML). Since the FDA approval, more than 300 natalizumab-associated PML cases have been documented among more than 100,000 treated MS patients. MRI is a crucial tool in the surveillance of patients treated with natalizumab in order to detect possible signs of PML in the asymptomatic stage. Although classical imaging characteristics of PML are well established, MRI findings in natalizumab-associated PML, particularly in early disease stages, show rather new and heterogeneous imaging findings including different patterns of inflammation with contrast enhancement. This review provides a comprehensive overview of the heterogeneous imaging findings in natalizumab-associated PML in the context of the underlying pathophysiology, histopathology, and the diagnostic procedure. We describe the MRI patterns of PML lesion evolution and complications including immune reconstitution inflammatory syndrome (IRIS). Finally, we present guidelines to differentiate MRI findings in PML from inflammatory demyelinating lesions, to facilitate the early diagnosis of PML in patients treated with natalizumab. [PUBLICATION ABSTRACT]
Author Wattjes, Mike P
Cadavid, Diego
Killestein, Joep
Richert, Nancy D
de Vos, Marlieke
Snaebjornsson, Petur
Barkhof, Frederik
Sanchez, Esther
Author_xml – sequence: 1
  givenname: Mike P
  surname: Wattjes
  fullname: Wattjes, Mike P
  email: m.wattjes@vumc.nl
– sequence: 2
  givenname: Nancy D
  surname: Richert
  fullname: Richert, Nancy D
– sequence: 3
  givenname: Joep
  surname: Killestein
  fullname: Killestein, Joep
– sequence: 4
  givenname: Marlieke
  surname: de Vos
  fullname: de Vos, Marlieke
– sequence: 5
  givenname: Esther
  surname: Sanchez
  fullname: Sanchez, Esther
– sequence: 6
  givenname: Petur
  surname: Snaebjornsson
  fullname: Snaebjornsson, Petur
– sequence: 7
  givenname: Diego
  surname: Cadavid
  fullname: Cadavid, Diego
– sequence: 8
  givenname: Frederik
  surname: Barkhof
  fullname: Barkhof, Frederik
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27998736$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/24192217$$D View this record in MEDLINE/PubMed
BookMark eNp9kUuLFTEQhYOMOA_du5IGEdy0JulO0u1OhvEBA27GdVOdrtybMZ1ck_TA-Df8w5P7GJQLusqjvnOoOnVOTnzwSMhLRt8xptR71gjeik6Uk1HO2yfkjLVK1bRX9KTcS7ne1k_JeUq3lFKlGvGMnPKW9ZwzdUZ-36yx0muY0WHwVTCVxyUG642DeYZsg_9QzbDymK2uIqbgwWusbPmzfrWVRtAZo00FSDsDyODsr2WGsYaUgraQcao2MayKPtk7rObFZWuCBlc5XH4ELJabNbiwgby-f06eGnAJXxzOC_L909XN5Zf6-tvnr5cfr2vdSpZrnIQaRac0yElSoTpu2CiwFaOYhEBVKi03ctJYcpDUNNBy7FVvmp4aXt4X5O3et7T2c8GUh9kmjc6Bx7CkgbWSs042VBT09RF6G5boS3c7irKmY1vq1YFaxhmnYRNLTPF-eIy7AG8OAKQyvIklS5v-cKrvO9XIwsk9p2NIKaIZtM27ZeQI1g2MDtv9D8f7L0J6JHz0_o-k3ksSrPCvsf7FPwACeMAs
CitedBy_id crossref_primary_10_1097_MS9_0000000000000712
crossref_primary_10_1007_s00062_015_0430_y
crossref_primary_10_1038_nrneurol_2015_157
crossref_primary_10_1136_jnnp_2017_316886
crossref_primary_10_1007_s11604_025_01837_y
crossref_primary_10_1002_ana_25070
crossref_primary_10_1212_NXI_0000000000000171
crossref_primary_10_1038_nrneurol_2018_14
crossref_primary_10_1007_s11882_014_0499_4
crossref_primary_10_1148_radiol_2015150673
crossref_primary_10_1136_jnnp_2014_309069
crossref_primary_10_1155_2016_5876798
crossref_primary_10_3389_fneur_2017_00454
crossref_primary_10_1186_s12883_019_1306_6
crossref_primary_10_1136_jnnp_2015_311100
crossref_primary_10_1177_1352458517750765
crossref_primary_10_1155_2014_307872
crossref_primary_10_1002_ana_24110
crossref_primary_10_1177_1352458515570768
crossref_primary_10_1002_ana_24153
crossref_primary_10_1002_ana_24471
crossref_primary_10_1016_j_jocn_2015_08_027
crossref_primary_10_1586_14737175_2016_1169924
crossref_primary_10_1177_1756286419836571
crossref_primary_10_1007_s00330_020_07362_y
crossref_primary_10_1111_imj_12558
crossref_primary_10_3389_fneur_2017_00294
crossref_primary_10_1177_1352458521999651
crossref_primary_10_1093_brain_awab419
crossref_primary_10_1097_WCO_0000000000000099
crossref_primary_10_1016_j_nic_2016_12_002
crossref_primary_10_1136_jnnp_2015_311411
crossref_primary_10_1002_acn3_114
crossref_primary_10_1136_jnnp_2016_313772
crossref_primary_10_1002_ana_24148
crossref_primary_10_1007_s00415_014_7530_5
crossref_primary_10_1259_bjr_20160721
crossref_primary_10_1016_j_msard_2023_104830
crossref_primary_10_1111_neup_12562
crossref_primary_10_1186_s12883_019_1407_2
crossref_primary_10_1007_s00415_014_7620_4
crossref_primary_10_1016_j_lpm_2021_104067
crossref_primary_10_1136_jnnp_2014_308630
crossref_primary_10_1155_2015_809252
crossref_primary_10_1007_s00415_014_7336_5
crossref_primary_10_36290_neu_2016_080
crossref_primary_10_1097_WCO_0000000000000200
crossref_primary_10_1212_WNL_0000000000002586
crossref_primary_10_1016_j_jns_2015_04_010
crossref_primary_10_1177_1352458515615225
crossref_primary_10_1007_s00415_014_7311_1
crossref_primary_10_1016_S1474_4422_21_00095_8
crossref_primary_10_1038_s41582_020_00427_y
crossref_primary_10_1186_s12885_017_3415_1
crossref_primary_10_1002_jca_21562
crossref_primary_10_1016_j_jns_2014_09_007
crossref_primary_10_1177_1352458516681505
crossref_primary_10_1007_s15016_016_5400_3
crossref_primary_10_1097_RCT_0000000000000719
crossref_primary_10_36290_neu_2017_086
crossref_primary_10_1111_ene_13906
crossref_primary_10_1212_NXI_0000000000000904
crossref_primary_10_1007_s11055_018_0619_z
Cites_doi 10.1136/jnnp.57.8.994
10.1212/WNL.0b013e31821a446b
10.1212/01.WNL.0000081306.86961.33
10.1002/ana.22137
10.1212/01.wnl.0000343735.44983.5e
10.1016/S1473-3099(09)70226-9
10.1007/s00401-011-0900-5
10.1212/WNL.0b013e31826846b4
10.1007/s00234-003-1115-9
10.1016/S1473-3099(10)70026-8
10.1001/archneurol.2009.57
10.1212/WNL.0b013e318253d61e
10.1016/S1474-4422(10)70028-4
10.3389/fneur.2013.00011
10.1056/NEJMoa054693
10.1212/WNL.0b013e318246d6d8
10.1146/annurev-pathol-020712-164018
10.1177/1352458512448268
10.1212/WNL.0b013e31824528a0
10.3174/ajnr.A3183
10.1097/NEN.0b013e31825caf2c
10.1007/s00415-007-0754-x
10.1093/brain/81.1.93
10.1007/s00234-007-0216-2
10.1212/WNL.0b013e31823b9c8f
10.1212/01.wnl.0000284601.54436.e4
10.1001/jamaneurol.2013.598
10.1097/NEN.0b013e31823ede59
10.1007/s004150050243
10.1136/jnnp-2013-304986
10.1136/jnnp-2012-302478
10.1056/NEJMoa0810257
10.1212/WNL.0b013e31822e55e7
10.1177/1352458513481010
10.1007/s00234-009-0512-0
10.1111/j.1440-1789.2008.00981.x
10.1056/NEJMoa0810316
10.1136/jnnp-2011-300511
10.1128/JVI.51.2.458-469.1984
10.1212/01.wnl.0000277457.17420.b5
10.1002/ana.21619
10.1177/1352458512460604
10.1177/1352458511435105
10.1212/WNL.61.6.734
10.1016/S0140-6736(71)91777-6
10.1001/archneurol.2009.31
10.1212/WNL.0b013e3182735cb3
10.1056/NEJMoa1107829
10.1016/j.crad.2010.03.001
10.1212/WNL.0b013e31823b9b27
10.1002/ana.20431
10.1016/j.nic.2012.02.010
10.1212/WNL.0b013e31820b7644
10.1002/ana.20933
10.1212/WNL.33.11.1444
10.1212/01.wnl.0000194227.16696.11
10.1212/WNL.0b013e3182768983
10.3174/ajnr.A3184
10.1002/ana.23676
10.1016/S1474-4422(10)70040-5
10.1016/S1474-4422(11)70149-1
10.1016/j.nic.2007.12.007
10.1080/13550280701469178
10.1038/nrneurol.2010.164
10.1212/WNL.0b013e31828c2fa1
10.1001/jamaneurol.2013.1960
ContentType Journal Article
Copyright The Author(s) 2013
2015 INIST-CNRS
SAGE Publications © Dec 2013
Copyright_xml – notice: The Author(s) 2013
– notice: 2015 INIST-CNRS
– notice: SAGE Publications © Dec 2013
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7TK
7U9
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
FYUFA
GHDGH
H94
K9-
K9.
M0R
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1177/1352458513510224
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Neurosciences Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
Consumer Health Database
ProQuest Health & Medical Complete (Alumni)
Consumer Health Database
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Family Health (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
CrossRef

ProQuest One Academic Middle East (New)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1477-0970
EndPage 1840
ExternalDocumentID 3138859121
24192217
27998736
10_1177_1352458513510224
10.1177_1352458513510224
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
-TM
.2E
.2F
.2G
.2J
.2N
01A
0R~
123
18M
1~K
29M
31R
31S
31U
31X
31Y
31Z
36B
39C
4.4
53G
54M
5VS
7X7
88E
8FI
8FJ
8R4
8R5
AABMB
AABOD
AACKU
AACMV
AACTG
AADUE
AAEWN
AAGGD
AAGLT
AAGMC
AAJIQ
AAJOX
AAJPV
AAKGS
AANSI
AAPEO
AAQDB
AAQXH
AAQXI
AARDL
AARIX
AATAA
AATBZ
AAUAS
AAXOT
AAYTG
AAZBJ
ABAFQ
ABAWC
ABAWP
ABCCA
ABCJG
ABDWY
ABEIX
ABFWQ
ABHFT
ABHKI
ABHQH
ABIDT
ABJIS
ABJNI
ABJZC
ABKRH
ABLUO
ABNCE
ABPGX
ABPNF
ABQKF
ABQXT
ABRHV
ABUJY
ABUWG
ABVFX
ABVVC
ABYTW
ACARO
ACDSZ
ACDXX
ACFEJ
ACFMA
ACFYK
ACGBL
ACGFO
ACGFS
ACGZU
ACJER
ACJTF
ACLFY
ACLHI
ACLZU
ACNXM
ACOFE
ACOXC
ACPRK
ACROE
ACRPL
ACSIQ
ACUAV
ACUIR
ACXKE
ACXMB
ADBBV
ADDLC
ADEBD
ADEIA
ADMPF
ADNBR
ADNMO
ADNON
ADRRZ
ADSTG
ADTBJ
ADUCT
ADUKL
ADVBO
ADYCS
ADZYD
ADZZY
AECGH
AECVZ
AEDTQ
AEKYL
AENEX
AEPTA
AEQLS
AERKM
AESZF
AEUHG
AEWDL
AEWHI
AEXFG
AEXNY
AFEET
AFKBI
AFKRA
AFKRG
AFMOU
AFQAA
AFUIA
AFVCE
AFWMB
AGHKR
AGKLV
AGNHF
AGPXR
AGQPQ
AGWFA
AGWNL
AHDMH
AHHFK
AHMBA
AIGRN
AJABX
AJEFB
AJMMQ
AJSCY
AJUZI
AJXAJ
AJXGE
ALIPV
ALKWR
ALMA_UNASSIGNED_HOLDINGS
AMCVQ
ANDLU
ARTOV
ASPBG
AUTPY
AVWKF
AYAKG
AZFZN
AZQEC
B3H
B8M
B8O
B8R
B8Z
B93
B94
BBRGL
BDDNI
BENPR
BKIIM
BKNYI
BKSCU
BPACV
BPHCQ
BSEHC
BVXVI
BWJAD
BYIEH
CAG
CBRKF
CCPQU
CDWPY
CFDXU
COF
CORYS
CQQTX
CS3
CUTAK
DB0
DC-
DC0
DD-
DD0
DE-
DF0
DO-
DOPDO
DU5
DV7
DV9
D~Y
EBS
EJD
EMOBN
F5P
FD6
FEDTE
FHBDP
FYUFA
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
H13
HF~
HMCUK
HVGLF
HZ~
J8X
K.F
K.J
K9-
M0R
M1P
N9A
O9-
P.B
P2P
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
Q1R
Q2X
Q7K
Q7L
Q7R
Q7U
Q7X
Q82
Q83
ROL
S01
SASJQ
SAUOL
SCNPE
SDB
SFB
SFC
SFK
SFN
SFT
SGA
SGO
SGP
SGR
SGV
SGX
SGZ
SHG
SNB
SPJ
SPQ
SPV
SQCSI
STM
UKHRP
XJT
ZONMY
ZPPRI
ZRKOI
ZSSAH
0SE
AAEJI
AAPII
AAYXX
ABUAX
AFFHD
AJGYC
AJHME
AJVBE
CITATION
PJZUB
PPXIY
ALTZF
IQODW
M4V
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7TK
7U9
7XB
8FK
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
ID FETCH-LOGICAL-c461t-ed57b587ca6d605782f1b5e45b5d55e787c42f6dce13560f3a42e979f390f20f3
IEDL.DBID 7X7
ISICitedReferencesCount 80
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000327311100007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1352-4585
1477-0970
IngestDate Sun Sep 28 10:41:02 EDT 2025
Mon Oct 06 18:03:46 EDT 2025
Thu Apr 03 06:59:31 EDT 2025
Wed Apr 02 07:25:05 EDT 2025
Sat Nov 29 08:12:59 EST 2025
Tue Nov 18 22:04:53 EST 2025
Tue Jun 17 22:26:05 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 14
Keywords Multiple sclerosis
magnetic resonance imaging
progressive multifocal leukoencephalopathy
natalizumab
Nervous system diseases
Natalizumab
Nuclear magnetic resonance imaging
Inflammatory disease
Cerebral disorder
Progressive multifocal leukoencephalopathy
Infection
Virus
Viral disease
Central nervous system disease
Medical imagery
Degenerative disease
Slow virus
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c461t-ed57b587ca6d605782f1b5e45b5d55e787c42f6dce13560f3a42e979f390f20f3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
PMID 24192217
PQID 1462013815
PQPubID 38324
PageCount 15
ParticipantIDs proquest_miscellaneous_1462186305
proquest_journals_1462013815
pubmed_primary_24192217
pascalfrancis_primary_27998736
crossref_citationtrail_10_1177_1352458513510224
crossref_primary_10_1177_1352458513510224
sage_journals_10_1177_1352458513510224
PublicationCentury 2000
PublicationDate 2013-12-01
PublicationDateYYYYMMDD 2013-12-01
PublicationDate_xml – month: 12
  year: 2013
  text: 2013-12-01
  day: 01
PublicationDecade 2010
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: London
– name: England
PublicationTitle Multiple sclerosis
PublicationTitleAlternate Mult Scler
PublicationYear 2013
Publisher SAGE Publications
Sage Publications
Sage Publications Ltd
Publisher_xml – name: SAGE Publications
– name: Sage Publications
– name: Sage Publications Ltd
References Sweeney, Manji, Miller 1994; 57
Seewann, Vrenken, van der Valk 2009; 66
Tan, McArthur, Clifford 2011; 77
Boster, Nicholas, Topalli 2013; 70
Vermersch, Kappos, Gold 2011; 76
Wattjes, Verhoeff, Zentjens 2013; 84
Eisele, Szabo, Griebe
Tan, Koralnik 2010; 9
Clifford, De Luca, Simpson 2010; 9
Sørensen, Bertolotto, Edan 2012; 18
Kilsdonk, de Graaf, Barkhof 2012; 22
Frisque, Bream, Canella 1984; 51
Phan-Ba, Belachew, Outteryck 2012; 79
Kuhle, Gosert, Bühler 2011; 77
Müller, Wandel, Colebunders 2010; 10
Koralnik 2006; 60
Mentzer, Prestel, Adams 2012; 83
Lindå, von Heijne, Major 2009; 361
van Waesberghe, van Walderveen, Castelijns 1998; 19
Koralnik, Wüthrich, Dang 2005; 57
Cañellas, Gols, Izquierdo 2007; 49
Visser, Wattjes, Pouwels 2012; 79
Du Pasquier, Corey, Margolin 2003; 61
Ryschkewitsch, Jensen, Monaco 2010; 68
Blinkenberg, Sellebjerg, Leffers 2013; 19
Kappos, Bates, Edan 2011; 10
Gheuens, Smith, Wang 2012; 78
Calabresi, Giovannoni, Confavreux 2007; 69
Wattjes, Barkhof 2009; 51
Berger, Aksamit, Clifford 2013; 80
Post, Thurnher, Clifford 2013; 34
Metz, Radue, Oterino 2012; 123
Moll, Rietsch, Ransohoff 2008; 70
Astrom, Mancall, Richardson 1958; 81
Vennegoor, Rispens, Strijbis 2012; 19
Antoniol, Jilek, Schluep 2012; 79
Seewann, Enzinger, Filippi 2008; 255
Brew, Davies, Cinque 2010; 6
Cinque, Koralnik, Gerevini 2009; 9
Takeda, Yamazaki, Miyakawa 2009; 29
Seewann, Kooi, Roosendaal 2012; 78
Bernal-Cano, Joseph, Koralnik 2007; 13
Berger 2009; 72
Bloomgren, Richman, Hotermans 2012; 366
Vennegoor, Wattjes, van Munster 2011; 76
Bergui, Bradac, Oguz 2004; 46
Tyler 2003; 61
Rossi 2008; 18
Wüthrich, Koralnik 2012; 71
Gheuens, Wüthrich, Koralnik 2013; 8
Boster, Hreha, Berger 2009; 66
Lindå, von Heijne 2013; 4
Bienfait, Louwerse, Portegies 1998; 245
Kurtzke 1983; 33
Richert, Bloomgren, Cadavid 2012; 18 27
Sha, Bag, Chapman 2010; 65
Berger, Clifford 2011; 77
Blair, Brew, Halpern 2012; 78
Décard, Haghikia, Tönnes 2013; 19
Kleinschmidt-DeMasters, Miravalle, Schowinsky 2012; 71
Lima, Drislane, Koralnik 2006; 66
Yousry, Pelletier, Cadavid 2012; 72
Wütrich, Dang, Westmoreland 2009; 65
Padget, Walker, ZuRhein 1971; 1
Rudick, Polman, Clifford 2013; 70
Yousry, Major, Ryschkewitsch 2006; 354
Phan-Ba, Lommers, Tshibanda 2012; 83
Wenning, Haghikia, Laubenberger 2009; 361
bibr46-1352458513510224
bibr71-1352458513510224
bibr20-1352458513510224
bibr62-1352458513510224
bibr63-1352458513510224
bibr37-1352458513510224
bibr11-1352458513510224
bibr8-1352458513510224
bibr72-1352458513510224
bibr21-1352458513510224
bibr64-1352458513510224
Dong-Si T (bibr38-1352458513510224)
bibr47-1352458513510224
bibr7-1352458513510224
bibr29-1352458513510224
bibr55-1352458513510224
bibr12-1352458513510224
bibr22-1352458513510224
bibr19-1352458513510224
bibr30-1352458513510224
bibr35-1352458513510224
bibr48-1352458513510224
bibr56-1352458513510224
bibr43-1352458513510224
bibr69-1352458513510224
bibr6-1352458513510224
bibr53-1352458513510224
bibr4-1352458513510224
bibr9-1352458513510224
bibr58-1352458513510224
bibr66-1352458513510224
bibr45-1352458513510224
Karnofsky DA (bibr60-1352458513510224) 1949
bibr32-1352458513510224
bibr61-1352458513510224
bibr1-1352458513510224
Eisele P (bibr31-1352458513510224)
bibr14-1352458513510224
bibr40-1352458513510224
bibr27-1352458513510224
bibr41-1352458513510224
van Waesberghe JH (bibr65-1352458513510224) 1998; 19
bibr16-1352458513510224
bibr59-1352458513510224
bibr33-1352458513510224
bibr2-1352458513510224
bibr17-1352458513510224
bibr24-1352458513510224
bibr50-1352458513510224
bibr67-1352458513510224
bibr34-1352458513510224
Post MJ (bibr54-1352458513510224) 2013; 34
bibr68-1352458513510224
bibr25-1352458513510224
bibr51-1352458513510224
bibr3-1352458513510224
bibr42-1352458513510224
bibr26-1352458513510224
bibr52-1352458513510224
bibr13-1352458513510224
bibr28-1352458513510224
bibr15-1352458513510224
bibr49-1352458513510224
bibr18-1352458513510224
bibr36-1352458513510224
bibr70-1352458513510224
Richert N (bibr39-1352458513510224) 2012; 18
bibr44-1352458513510224
bibr23-1352458513510224
bibr57-1352458513510224
bibr5-1352458513510224
bibr10-1352458513510224
References_xml – volume: 18 27
  start-page: P99
  year: 2012
  article-title: Imaging findings for PML in natalizumab-treated MS patients
  publication-title: Mult Scler
– volume: 84
  start-page: 1176
  year: 2013
  end-page: 1177
  article-title: Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: Productive JC virus infection or preclinical PML-IRIS manifestation?
  publication-title: J Neurol Neurosurg Psychiatry
– volume: 9
  start-page: 438
  year: 2010
  end-page: 446
  article-title: Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: Lessons from 28 cases
  publication-title: Lancet Neurol
– volume: 69
  start-page: 1391
  year: 2007
  end-page: 1403
  article-title: The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL
  publication-title: Neurology
– volume: 9
  start-page: 425
  year: 2010
  end-page: 437
  article-title: Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis
  publication-title: Lancet Neurol
– volume: 46
  start-page: 22
  year: 2004
  end-page: 25
  article-title: Progressive multifocal leukoencephalopathy: Diffusion-weighted imaging and pathological correlations
  publication-title: Neuroradiology
– volume: 61
  start-page: 775
  year: 2003
  end-page: 782
  article-title: Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual
  publication-title: Neurology
– volume: 22
  start-page: 135
  year: 2012
  end-page: 157
  article-title: Inflammation high-field magnetic resonance imaging
  publication-title: Neuroimaging Clin N Am
– volume: 80
  start-page: 1430
  year: 2013
  end-page: 1438
  article-title: PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section
  publication-title: Neurology
– volume: 71
  start-page: 604
  year: 2012
  end-page: 617
  article-title: Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab
  publication-title: J Neuropathol Exp Neurol
– volume: 76
  start-page: 1697
  year: 2011
  end-page: 1704
  article-title: Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
  publication-title: Neurology
– volume: 51
  start-page: 279
  year: 2009
  end-page: 292
  article-title: High field MRI in the diagnosis of multiple sclerosis: High field-high yield?
  publication-title: Neuroradiology
– volume: 33
  start-page: 1444
  year: 1983
  end-page: 1452
  article-title: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
  publication-title: Neurology
– volume: 77
  start-page: 2010
  year: 2011
  end-page: 2016
  article-title: Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS
  publication-title: Neurology
– volume: 72
  start-page: 1454
  year: 2009
  end-page: 1455
  article-title: Steroids for PML-IRIS: A double-edged sword?
  publication-title: Neurology
– volume: 9
  start-page: 625
  year: 2009
  end-page: 636
  article-title: Progressive multifocal leukoencephalopathy in HIV-1 infection
  publication-title: Lancet Infect Dis
– volume: 19
  start-page: 249
  year: 2013
  end-page: 251
  article-title: Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy
  publication-title: Mult Scler
– volume: 8
  start-page: 189
  year: 2013
  end-page: 215
  article-title: Progressive multifocal leukoencephalopathy: Why gray and white matter
  publication-title: Annu Rev Pathol
– volume: 34
  start-page: 1297
  year: 2013
  end-page: 1307
  article-title: CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 1: Overview and discussion of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome and cryptococcal-immune reconstitution inflammatory syndrome
  publication-title: AJNR Am J Neuroradiol
– volume: 66
  start-page: 262
  year: 2006
  end-page: 264
  article-title: Seizures and their outcome in progressive multifocal leukoencephalopathy
  publication-title: Neurology
– volume: 79
  start-page: 2258
  year: 2012
  end-page: 2264
  article-title: Impairment of JCV-specific T-cell response by corticotherapy: Effect on PML-IRIS management
  publication-title: Neurology
– volume: 19
  start-page: 675
  year: 1998
  end-page: 683
  article-title: Patterns of lesion development in multiple sclerosis: Longitudinal observations with T1-weighted spin-echo and magnetization transfer MR
  publication-title: AJNR Am J Neuroradiol
– volume: 83
  start-page: 927
  year: 2012
  end-page: 933
  article-title: Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies
  publication-title: J Neurol Neurosurg Psychiatry
– volume: 81
  start-page: 93
  year: 1958
  end-page: 127
  article-title: Progressive multifocal leukoencephalopathy
  publication-title: Brain
– volume: 70
  start-page: 172
  year: 2013
  end-page: 182
  article-title: Natalizumab: Bench to bedside and beyond
  publication-title: JAMA Neurol
– volume: 66
  start-page: 601
  year: 2009
  end-page: 609
  article-title: Diffusely abnormal white matter in chronic multiple sclerosis: Imaging and histopathologic analysis
  publication-title: Arch Neurol
– volume: 19
  start-page: 593
  year: 2012
  end-page: 600
  article-title: Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis
  publication-title: Mult Scler
– volume: 4
  start-page: 11
  year: 2013
  article-title: Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy
  publication-title: Front Neurol
– volume: 70
  start-page: 336
  year: 2008
  end-page: 343
  article-title: Cortical demyelination in PML and MS: Similarities and differences
  publication-title: Neurology
– volume: 123
  start-page: 235
  year: 2012
  end-page: 245
  article-title: Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy
  publication-title: Acta Neuropathol
– volume: 57
  start-page: 994
  year: 1994
  end-page: 997
  article-title: Cortical and subcortical JC virus infection: Two unusual cases of AIDS associated progressive multifocal leukoencephalopathy
  publication-title: J Neurol Neurosurg Psychiatry
– volume: 6
  start-page: 667
  year: 2010
  end-page: 679
  article-title: Progressive multifocal leukoencephalopathy and other forms of JC virus disease
  publication-title: Nat Rev Neurol
– volume: 78
  start-page: 1390
  year: 2012
  end-page: 1393
  article-title: Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS
  publication-title: Neurology
– volume: 13
  start-page: 474
  year: 2007
  end-page: 476
  article-title: Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient
  publication-title: J Neurovirol
– volume: 76
  start-page: 574
  year: 2011
  end-page: 576
  article-title: Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS
  publication-title: Neurology
– volume: 66
  start-page: 593
  year: 2009
  end-page: 599
  article-title: Progressive multifocal leukoencephalopathy and relapsing–remitting multiple sclerosis: A comparative study
  publication-title: Arch Neurol
– volume: 18
  start-page: 149
  year: 2008
  end-page: 161
  article-title: Imaging of acute disseminated encephalomyelitis
  publication-title: Neuroimaging Clin N Am
– volume: 71
  start-page: 54
  year: 2012
  end-page: 65
  article-title: Frequent infection of cortical neurons in JC virus patients with progressive multifocal leukoencephalopathy
  publication-title: J Neuropathol Exp Neurol
– volume: 79
  start-page: 1067
  year: 2012
  end-page: 1069
  article-title: The earlier, the smaller, the better for natalizumab-associated PML: In MRI vigilance veritas?
  publication-title: Neurology
– volume: 65
  start-page: 742
  year: 2009
  end-page: 748
  article-title: Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons
  publication-title: Ann Neurol
– volume: 70
  start-page: 398
  year: 2013
  end-page: 402
  article-title: Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab
  publication-title: JAMA Neurol
– article-title: Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy
  publication-title: J Neuroimaging
– volume: 255
  start-page: 1
  year: 2008
  end-page: 10
  article-title: MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: A review of reported findings
  publication-title: J Neurol
– volume: 29
  start-page: 485
  year: 2009
  end-page: 493
  article-title: Progressive multifocal leukoencephalopathy showing extensive spinal cord involvement in a patient with lymphocytopenia
  publication-title: Neuropathology
– volume: 57
  start-page: 576
  year: 2005
  end-page: 580
  article-title: JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy
  publication-title: Ann Neurol
– volume: 1
  start-page: 1257
  year: 1971
  end-page: 1260
  article-title: Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy
  publication-title: Lancet
– volume: 361
  start-page: 1075
  year: 2009
  end-page: 1080
  article-title: Treatment of progressive multifocal leukoencephalopathy associated with natalizumab
  publication-title: N Engl J Med
– volume: 34
  start-page: 1308
  year: 2013
  end-page: 1318
  article-title: CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 2: Discussion of neuro-immune reconstitution inflammatory syndrome with and without other pathogens
  publication-title: AJNR Am J Neuroradiol
– volume: 77
  start-page: 2006
  year: 2011
  end-page: 2007
  article-title: The manifold faces of PML and the challenge of diagnosis
  publication-title: Neurology
– volume: 19
  start-page: 1226
  year: 2013
  end-page: 1229
  article-title: Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab
  publication-title: Mult Scler
– volume: 245
  start-page: 557
  year: 1998
  end-page: 558
  article-title: Progressive multifocal leukoencephalopathy presenting as a solitary gray matter lesion
  publication-title: J Neurol
– volume: 10
  start-page: 251
  year: 2010
  end-page: 261
  article-title: Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: A systematic review and meta-analysis
  publication-title: Lancet Infect Dis
– volume: 72
  start-page: 779
  year: 2012
  end-page: 787
  article-title: MRI pattern in natalizumab-associated progressive multifocal leukoencephalopathy
  publication-title: Ann Neurol
– volume: 60
  start-page: 162
  year: 2006
  end-page: 173
  article-title: Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?
  publication-title: Ann Neurol
– volume: 49
  start-page: 393
  year: 2007
  end-page: 409
  article-title: Idiopathic inflammatory-demyelinating diseases of the central nervous system
  publication-title: Neuroradiology
– volume: 68
  start-page: 384
  year: 2010
  end-page: 391
  article-title: JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab
  publication-title: Ann Neurol
– volume: 83
  start-page: 224
  year: 2012
  end-page: 226
  article-title: MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy
  publication-title: J Neurol Neurosurg Psychiatry
– volume: 354
  start-page: 924
  year: 2006
  end-page: 933
  article-title: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
  publication-title: N Engl J Med
– volume: 51
  start-page: 458
  year: 1984
  end-page: 469
  article-title: Human polyomavirus JC virus genome
  publication-title: J Virol
– volume: 77
  start-page: 1061
  year: 2011
  end-page: 1067
  article-title: Immune reconstitution inflammatory syndrome in natalizumab-associated PML
  publication-title: Neurology
– volume: 366
  start-page: 1870
  year: 2012
  end-page: 1880
  article-title: Risk of natalizumab-associated progressive multifocal leuko-encephalopathy
  publication-title: N Engl J Med
– volume: 361
  start-page: 1081
  year: 2009
  end-page: 1087
  article-title: Progressive multifocal leukoencephalopathy after natalizumab monotherapy
  publication-title: N Engl J Med
– volume: 78
  start-page: 507
  year: 2012
  end-page: 508
  article-title: Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance
  publication-title: Neurology
– volume: 78
  start-page: 302
  year: 2012
  end-page: 308
  article-title: Postmortem verification of MS cortical lesion detection with 3D DIR
  publication-title: Neurology
– volume: 79
  start-page: 2000
  year: 2012
  end-page: 2003
  article-title: Tumefactive multiple sclerosis lesions under fingolimod treatment
  publication-title: Neurology
– volume: 18
  start-page: 143
  year: 2012
  end-page: 152
  article-title: Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
  publication-title: Mult Scler
– volume: 65
  start-page: 431
  year: 2010
  end-page: 439
  article-title: Imaging manifestations of progressive multifocal leukoencephalopathy
  publication-title: Clin Radiol
– volume: 61
  start-page: 734
  year: 2003
  end-page: 735
  article-title: The uninvited guest: JC virus infection of neurons in PML
  publication-title: Neurology
– volume: 10
  start-page: 745
  year: 2011
  end-page: 758
  article-title: Natalizumab treatment for multiple sclerosis: Updated recommendations for patient selection and monitoring
  publication-title: Lancet Neurol
– ident: bibr47-1352458513510224
  doi: 10.1136/jnnp.57.8.994
– ident: bibr57-1352458513510224
  doi: 10.1212/WNL.0b013e31821a446b
– ident: bibr20-1352458513510224
  doi: 10.1212/01.WNL.0000081306.86961.33
– ident: bibr28-1352458513510224
  doi: 10.1002/ana.22137
– ident: bibr52-1352458513510224
  doi: 10.1212/01.wnl.0000343735.44983.5e
– ident: bibr4-1352458513510224
  doi: 10.1016/S1473-3099(09)70226-9
– ident: bibr58-1352458513510224
  doi: 10.1007/s00401-011-0900-5
– ident: bibr35-1352458513510224
  doi: 10.1212/WNL.0b013e31826846b4
– ident: bibr40-1352458513510224
  doi: 10.1007/s00234-003-1115-9
– ident: bibr56-1352458513510224
  doi: 10.1016/S1473-3099(10)70026-8
– ident: bibr42-1352458513510224
  doi: 10.1001/archneurol.2009.57
– ident: bibr50-1352458513510224
  doi: 10.1212/WNL.0b013e318253d61e
– ident: bibr5-1352458513510224
  doi: 10.1016/S1474-4422(10)70028-4
– ident: bibr37-1352458513510224
  doi: 10.3389/fneur.2013.00011
– ident: bibr8-1352458513510224
  doi: 10.1056/NEJMoa054693
– ident: bibr32-1352458513510224
  doi: 10.1212/WNL.0b013e318246d6d8
– ident: bibr18-1352458513510224
  doi: 10.1146/annurev-pathol-020712-164018
– ident: bibr72-1352458513510224
  doi: 10.1177/1352458512448268
– volume-title: Presented at the 65th Meeting of the American Academy of Neurology
  ident: bibr38-1352458513510224
– ident: bibr45-1352458513510224
  doi: 10.1212/WNL.0b013e31824528a0
– volume: 34
  start-page: 1297
  year: 2013
  ident: bibr54-1352458513510224
  publication-title: AJNR Am J Neuroradiol
  doi: 10.3174/ajnr.A3183
– ident: bibr46-1352458513510224
  doi: 10.1097/NEN.0b013e31825caf2c
– ident: bibr69-1352458513510224
  doi: 10.1007/s00415-007-0754-x
– ident: bibr1-1352458513510224
  doi: 10.1093/brain/81.1.93
– ident: bibr64-1352458513510224
  doi: 10.1007/s00234-007-0216-2
– ident: bibr30-1352458513510224
  doi: 10.1212/WNL.0b013e31823b9c8f
– start-page: 196
  volume-title: Evaluation of chemotherapeutic agents
  year: 1949
  ident: bibr60-1352458513510224
– ident: bibr43-1352458513510224
  doi: 10.1212/01.wnl.0000284601.54436.e4
– ident: bibr7-1352458513510224
  doi: 10.1001/jamaneurol.2013.598
– ident: bibr12-1352458513510224
– ident: bibr19-1352458513510224
  doi: 10.1097/NEN.0b013e31823ede59
– ident: bibr48-1352458513510224
  doi: 10.1007/s004150050243
– ident: bibr49-1352458513510224
  doi: 10.1136/jnnp-2013-304986
– ident: bibr24-1352458513510224
  doi: 10.1136/jnnp-2012-302478
– ident: bibr31-1352458513510224
  publication-title: J Neuroimaging
– ident: bibr59-1352458513510224
  doi: 10.1056/NEJMoa0810257
– ident: bibr26-1352458513510224
  doi: 10.1212/WNL.0b013e31822e55e7
– ident: bibr36-1352458513510224
  doi: 10.1177/1352458513481010
– ident: bibr67-1352458513510224
  doi: 10.1007/s00234-009-0512-0
– ident: bibr15-1352458513510224
  doi: 10.1111/j.1440-1789.2008.00981.x
– volume: 18
  start-page: P99
  year: 2012
  ident: bibr39-1352458513510224
  publication-title: Mult Scler
– ident: bibr27-1352458513510224
  doi: 10.1056/NEJMoa0810316
– ident: bibr34-1352458513510224
  doi: 10.1136/jnnp-2011-300511
– ident: bibr3-1352458513510224
  doi: 10.1128/JVI.51.2.458-469.1984
– ident: bibr63-1352458513510224
  doi: 10.1212/01.wnl.0000277457.17420.b5
– ident: bibr22-1352458513510224
  doi: 10.1002/ana.21619
– ident: bibr62-1352458513510224
  doi: 10.1177/1352458512460604
– ident: bibr11-1352458513510224
  doi: 10.1177/1352458511435105
– ident: bibr44-1352458513510224
  doi: 10.1212/WNL.61.6.734
– ident: bibr2-1352458513510224
  doi: 10.1016/S0140-6736(71)91777-6
– ident: bibr66-1352458513510224
  doi: 10.1001/archneurol.2009.31
– ident: bibr70-1352458513510224
  doi: 10.1212/WNL.0b013e3182735cb3
– ident: bibr10-1352458513510224
  doi: 10.1056/NEJMoa1107829
– ident: bibr6-1352458513510224
  doi: 10.1016/j.crad.2010.03.001
– ident: bibr29-1352458513510224
  doi: 10.1212/WNL.0b013e31823b9b27
– ident: bibr21-1352458513510224
  doi: 10.1002/ana.20431
– ident: bibr68-1352458513510224
  doi: 10.1016/j.nic.2012.02.010
– ident: bibr41-1352458513510224
  doi: 10.1212/WNL.0b013e31820b7644
– ident: bibr17-1352458513510224
  doi: 10.1002/ana.20933
– ident: bibr61-1352458513510224
  doi: 10.1212/WNL.33.11.1444
– ident: bibr25-1352458513510224
  doi: 10.1212/01.wnl.0000194227.16696.11
– ident: bibr51-1352458513510224
  doi: 10.1212/WNL.0b013e3182768983
– ident: bibr55-1352458513510224
  doi: 10.3174/ajnr.A3184
– ident: bibr33-1352458513510224
  doi: 10.1002/ana.23676
– volume: 19
  start-page: 675
  year: 1998
  ident: bibr65-1352458513510224
  publication-title: AJNR Am J Neuroradiol
– ident: bibr13-1352458513510224
  doi: 10.1016/S1474-4422(10)70040-5
– ident: bibr9-1352458513510224
  doi: 10.1016/S1474-4422(11)70149-1
– ident: bibr71-1352458513510224
  doi: 10.1016/j.nic.2007.12.007
– ident: bibr16-1352458513510224
  doi: 10.1080/13550280701469178
– ident: bibr14-1352458513510224
  doi: 10.1038/nrneurol.2010.164
– ident: bibr23-1352458513510224
  doi: 10.1212/WNL.0b013e31828c2fa1
– ident: bibr53-1352458513510224
  doi: 10.1001/jamaneurol.2013.1960
SSID ssj0007735
Score 2.369963
SecondaryResourceType review_article
Snippet Natalizumab is a monoclonal antibody against α4-integrin approved for the treatment of multiple sclerosis (MS) due to a positive effect on clinical and...
SourceID proquest
pubmed
pascalfrancis
crossref
sage
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1826
SubjectTerms Animals
Antibodies, Monoclonal, Humanized - adverse effects
Biological and medical sciences
Brain - drug effects
Brain - pathology
Brain - virology
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Demyelinating Diseases - pathology
Diagnosis, Differential
Early Diagnosis
Human viral diseases
Humans
Immune Reconstitution Inflammatory Syndrome - chemically induced
Immune Reconstitution Inflammatory Syndrome - pathology
Immune Reconstitution Inflammatory Syndrome - virology
Immunologic Factors - adverse effects
Infectious diseases
Investigative techniques, diagnostic techniques (general aspects)
Leukoencephalopathy, Progressive Multifocal - chemically induced
Leukoencephalopathy, Progressive Multifocal - pathology
Leukoencephalopathy, Progressive Multifocal - virology
Magnetic Resonance Imaging
Medical sciences
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Natalizumab
Nervous system
Neuroimaging - methods
Neurology
Predictive Value of Tests
Radiodiagnosis. Nmr imagery. Nmr spectrometry
Viral diseases
Viral diseases of the nervous system
Title The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy
URI https://journals.sagepub.com/doi/full/10.1177/1352458513510224
https://www.ncbi.nlm.nih.gov/pubmed/24192217
https://www.proquest.com/docview/1462013815
https://www.proquest.com/docview/1462186305
Volume 19
WOSCitedRecordID wos000327311100007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Consumer Health Database
  customDbUrl:
  eissn: 1477-0970
  dateEnd: 20151231
  omitProxy: false
  ssIdentifier: ssj0007735
  issn: 1352-4585
  databaseCode: M0R
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/familyhealth
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1477-0970
  dateEnd: 20151231
  omitProxy: false
  ssIdentifier: ssj0007735
  issn: 1352-4585
  databaseCode: 7X7
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1477-0970
  dateEnd: 20151231
  omitProxy: false
  ssIdentifier: ssj0007735
  issn: 1352-4585
  databaseCode: BENPR
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED_BhtAkND43MkZlJITEQ9Tmw3bMCwK0iQdWTROgvlWO7bBqbVLWdhL8G_zD3DluuyLYCy9RksaW1fvdl-98B_BSCsdzIZC_ZWHiXFgZq8IZNORQYXCVutSfr_j6Sfb7xWCgTsOG2yykVS5lohfUtjG0R95Fjk4pqpbwt9PvMXWNouhqaKFxG7apbTbhXA5WDldPyoyvQ5PdBI2NnMJgGfeF1DZU0b2pnuG_UrXtLP5mb27kenn1c3z_fxf-AHaD4cnetUh5CLdc_QjunoTQ-mP4hYBh5lxPUA81NWsq5ktdIgARM-35xjdsor_VdOqRoZPeUKkOx0YT3-eIhl6v_OwnoK2h0c_FRJexDjBwlvmUMMq-vXLM5zNWpE_Z2C0uGpIz03M9bqhT8o8n8OX46POHj3Ho2BCbXCTz2FkuS15Io4VFPwmtjyopuct5yS3nDoWDydNKWOOQBqJXZTpPnZKqylSvSvF5D7bqpnZPgakUX6BwsIqXOcWGMmcSqzOZKGVTWUbQXRJvaEI5c-qqMR4moYL5n-SO4PVqxLQt5XHDt50NPKwGpBL9U5mJCA6X1B4Grp8N16SO4MXqZ-RXCsLo2jWL9pukEChmI9hvgbWenELy6CNG8IqQdm3ifyzz4OZVPIMdumuzbw5ha365cM_hjrmaj2aXHc8r_lp0YPv9Uf_0DJ9Oeme_AbzuHZo
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VggAJ8X4ESjESVOIQbePEcYyEEAKqVt2uOBS0t-DYDl2xmyz7KCp_g__Bb2Qmj90ugt564BjHtiz7m5dnPAPwTMZORHGM9C0T40exlb5KnEFFDgWGUNzx6n3Fp67s9ZJ-X31Yg1_tWxgKq2x5YsWobWnojryDFM3JqxaI1-NvPlWNIu9qW0KjhsW-O_mOJtv01d47PN_nnO-8P3y76zdVBXwTxcHMd1bITCTS6NiiLo8SMg8y4SKRCSuEQwCbiOexNS4IUR3IQx1xp6TKQ7Wdc_zGeS_AReTjkow92V8YeNtShmLpCu3geB6R2y0UVeK2FdF3bayneAp5XT7jb_rtSmxZJe52bvxvG3UTrjeKNXtTU8ItWHPFbbh80IQO3IGfSBDMHOkRytmyYGXOqlSeSGBIE_X7zZdspL8U9KqTTRyZKEgQbDCq6jjR0NOZrasJ6Opr8GM-0pmvG5g7y6qQN4ouPnasitfMSV9gQzf_WhIfHR_pYUmVoE_uwsdz2ZJ7sF6UhXsATHFsQOZnlcgi8n2FzgRWhzJQynKZedBpwZKaJl07VQ0ZpkGTof1PeHnwYjFiXKcqOaPv5gr-FgO4RPtbhrEHGy260oarTdMltDx4uviN_IicTLpw5bzuEyQxihEP7tdAXk5OIQdoA3uwRcg-NfE_lvnw7FU8gSu7hwfdtLvX238EV6m1jjTagPXZZO4ewyVzPBtMJ5sVnTL4fN54_w3tMnaF
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+chameleon+of+neuroinflammation%3A+magnetic+resonance+imaging+characteristics+of+natalizumab-associated+progressive+multifocal+leukoencephalopathy&rft.jtitle=Multiple+sclerosis&rft.au=PWATTJES%2C+Mike&rft.au=RICHERT%2C+Nancy+D&rft.au=KILLESTEIN%2C+Joep&rft.au=DE+VOS%2C+Marlieke&rft.date=2013-12-01&rft.pub=Sage+Publications&rft.issn=1352-4585&rft.volume=19&rft.issue=14&rft.spage=1826&rft.epage=1840&rft_id=info:doi/10.1177%2F1352458513510224&rft.externalDBID=n%2Fa&rft.externalDocID=27998736
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1352-4585&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1352-4585&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1352-4585&client=summon